| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.32 | 0.03 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.071 | 0.03 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.37 | 0.03 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | -0.34 | 0.04 |